Compare UIS & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UIS | SWKH |
|---|---|---|
| Founded | 1942 | 1996 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | EDP Services | Diversified Financial Services |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 205.9M |
| IPO Year | 1994 | N/A |
| Metric | UIS | SWKH |
|---|---|---|
| Price | $2.18 | $17.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $5.88 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 796.5K | 4.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,008,400,000.00 | N/A |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.11 | $13.00 |
| 52 Week High | $5.33 | $18.66 |
| Indicator | UIS | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 29.10 | 39.57 |
| Support Level | $2.16 | $16.82 |
| Resistance Level | $2.39 | $17.44 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 9.34 | 31.03 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.